Johnson & Johnson Publishes Transcript of Third Quarter 2025 Earnings Conference Call
Johnson & Johnson released the transcript of its Third Quarter 2025 Earnings Conference Call, held on October 14, 2025. The event featured key members of the company's leadership team, including the Chairman and CEO, the Chief Financial Officer, the Executive Vice President of Pharmaceuticals, and the Worldwide Chairman of MedTech. The call was attended by several analysts from leading financial institutions. During the call, Johnson & Johnson's management reviewed the company's third-quarter business results and provided an updated financial outlook. They highlighted ongoing pioneering treatments and strategies aimed at transforming lives. Management emphasized their commitment to innovation and market leadership, stating, "We are focused on pioneering treatments that are going to transform lives." The team also discussed the company's future operating and financial performance, market position, and business strategy, cautioning that forward-looking statements are subject to risks and uncertainties. The full transcript can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.